Premium
SLC 2A5 overexpression in childhood philadelphia chromosome‐positive acute lymphoblastic leukaemia
Author(s) -
Zhao Pan,
Huang Jingcao,
Zhang Dan,
Zhang Danfeng,
Wang Fangfang,
Qu Ying,
Guo Tingting,
Qin Yu,
Wei Jin,
Niu Ting,
Zheng Yuhuan
Publication year - 2018
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15580
Subject(s) - dasatinib , imatinib , cancer research , medicine , acute lymphocytic leukemia , tyrosine kinase , microarray analysis techniques , gene expression , biology , microbiology and biotechnology , gene , genetics , leukemia , receptor , lymphoblastic leukemia , myeloid leukemia
Summary To study glycolysis/glycogenesis‐related genes expression in childhood B‐cell acute lymphoblastic leukaemia (B‐ ALL ), we performed a microarray‐based analysis using published gene expression profiles. We found that SLC 2A5 , which encodes solute carrier family 2 member 5 ( SLC 2A5, previously termed GLUT 5) that facilitates cell fructose uptake, was up‐regulated in Philadelphia chromosome‐positive ALL (Ph+ ALL ). Microarray‐based analyses also suggested that SLC 2A5 expression was significantly down‐regulated in childhood B‐ ALL with t(1;19) or 11q23 mutation. High SLC 2A5 expression was found in patients who had disease recurrence within 3 years, early relapse, shortened complete remission duration and positive minimal residue disease ( MRD ) status after treatment. SLC 2A5 overexpression at both the mRNA and protein level in Ph+ ALL was confirmed in a validation cohort of childhood B‐ ALL . We also validated the correlation of SLC 2A5 expression and MRD status. A mechanistic study using a human Ph+ ALL cell line showed that BCR ‐ ABL 1 kinase might regulate SLC 2A5 expression via MYC . The tyrosine kinase inhibitors ( TKI s) imatinib and dasatinib repressed SLC 2A5 expression and the cell uptake of fructose. Fructose protected the tumour cells from nutrition deficiency and drug‐induced cell death. Overall, our findings showed that SLC 2A5 was up‐regulated in childhood Ph+ ALL . SLC 2A5 expression correlated with childhood B‐ ALL clinical factors, such as MRD status. Given that TKI s could inhibit SLC 2A5 expression, repression of fructose utility after TKI treatment contributes to TKI ‐induced Ph+ ALL cytotoxicity. Targeting SLC 2A5 might be promising in B‐ ALL treatment, especially for Ph+ ALL patients with high SLC 2A5 expression.